Aclarion, Inc. has established a commercial agreement with Weill Cornell Medicine to bring its Nociscan technology to Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center. The agreement supports a clinical trial entitled "A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate (BMAC) for Osteoarthritis and Degenerative Disc Disease," led by principal investigator Jaspal Ricky Singh, MD. This collaboration marks a significant step in applying augmented intelligence to spine care research.
The trial aims to investigate whether the dose and quantity of bone marrow aspirate stem cell concentrate used for treating osteoarthritis and degenerative disc disease affects patient-reported functional outcomes and pain. A subset of spine patients, selected through Dr. Singh's clinical evaluation, will be eligible for Nociscan assessment. Dr. Singh, Vice Chair and Director of Interventional Spine at Weill Cornell Medicine, stated that the team's pioneering research into discogenic low back pain and concentrated bone marrow aspirate presents an ideal opportunity to utilize Nociscan's insights.
Chronic low back pain represents a global healthcare challenge, with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain according to research cited in Global Spine Journal. Aclarion's Nociscan is described as the first evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine. The technology objectively quantifies chemical biomarkers associated with disc pain and, when used with other diagnostic tools, can provide critical insights into pain location.
The company notes that Nociscan improves pain and function when all Nociscan-positive discs are treated. The technology works by receiving magnetic resonance spectroscopy data from MRI machines through a cloud connection, where proprietary signal processing techniques extract and quantify chemical biomarkers. This data is then analyzed using proprietary algorithms to indicate whether a disc may be a pain source. For more information about Aclarion, visit https://www.aclarion.com. Those seeking a Nociscan center can view the site map at https://tinyurl.com/aconnewsroom.
This partnership between a commercial healthcare technology company and a leading academic medical center represents a convergence of clinical research and technological innovation in addressing a pervasive medical condition. The integration of Nociscan into Weill Cornell's multidisciplinary spine treatment approach, which includes physical therapy and various interventional techniques, could potentially enhance treatment precision for patients with chronic low back pain. As degenerative spine conditions continue to affect millions globally, collaborations like this one may contribute to more targeted and effective pain management strategies.
